Skip to main content

Articles

Page 16 of 39

  1. Hodgkin lymphoma (HL) is an uncommon B cell lymphoma. We assessed the global, regional, and national burden of HL from 1990 to 2017, by gender, age, and social-demographic index (SDI).

    Authors: Linghui Zhou, Yujiao Deng, Na Li, Yi Zheng, Tian Tian, Zhen Zhai, Si Yang, Qian Hao, Ying Wu, Dingli Song, Dai Zhang, Jun Lyu and Zhijun Dai
    Citation: Journal of Hematology & Oncology 2019 12:107
  2. Circular RNAs (circRNAs) represent a type of endogenous noncoding RNAs that are generated by back-splicing events and favor repetitive sequences. Recent studies have reported that cancer-associated chromosomal...

    Authors: Wei Huang, Ke Fang, Tian-Qi Chen, Zhan-Cheng Zeng, Yu-Meng Sun, Cai Han, Lin-Yu Sun, Zhen-Hua Chen, Qian-Qian Yang, Qi Pan, Xue-Qun Luo, Wen-Tao Wang and Yue-Qin Chen
    Citation: Journal of Hematology & Oncology 2019 12:103
  3. Early diagnosis of CNS lymphoma (CNSL) is essential for successful therapy of this rapidly progressing brain tumor. However, in patients presenting with focal brain lesions, fast and reliable diagnosis of PCNS...

    Authors: Matthias Mulazzani, Marion Huber, Sabine Borchard, Sigrid Langer, Barbara Angele, Elisabeth Schuh, Edgar Meinl, Martin Dreyling, Tobias Birnbaum, Andreas Straube, Uwe Koedel and Louisa von Baumgarten
    Citation: Journal of Hematology & Oncology 2019 12:102
  4. Hepatocellular carcinoma (HCC) is a lethal disease, and recurrence and metastasis are the major causes of death in HCC patients. Cancer-associated fibroblasts (CAFs), a major stromal cell type in the HCC micro...

    Authors: Zeli Yin, Chengyong Dong, Keqiu Jiang, Zhe Xu, Rui Li, Kun Guo, Shujuan Shao and Liming Wang
    Citation: Journal of Hematology & Oncology 2019 12:101
  5. Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with an incidence that increases with age, and a generally poor prognosis. The disease is clinically and genetically heterogene...

    Authors: Catherine Lai, Kimberley Doucette and Kelly Norsworthy
    Citation: Journal of Hematology & Oncology 2019 12:100
  6. Cancer immunotherapy has been regarded as the most significant scientific breakthrough of 2013, and antibody therapy is at the core of this breakthrough. Despite significant success achieved in recent years, i...

    Authors: Qinghua He, Zhaoyu Liu, Zhihua Liu, Yuxiong Lai, Xinke Zhou and Jinsheng Weng
    Citation: Journal of Hematology & Oncology 2019 12:99
  7. The immunogenicity of a cancer cell is derived from accumulated somatic mutations. However, on the contrary to increased immunogenicity, anti-cancer immune response tends to be feeble. This impaired anti-cance...

    Authors: Anping Li, Ming Yi, Shuang Qin, Qian Chu, Suxia Luo and Kongming Wu
    Citation: Journal of Hematology & Oncology 2019 12:98
  8. Chemoresistance is one of the main causes of poor prognosis in pancreatic cancer patients. Understanding the mechanisms implicated in chemoresistance of pancreatic cancer is critical to improving patient outco...

    Authors: Guangbing Xiong, Chang Liu, Gang Yang, Mengyu Feng, Jianwei Xu, Fangyu Zhao, Lei You, Li Zhou, Lianfang Zheng, Ya Hu, Xiaowo Wang, Taiping Zhang and Yupei Zhao
    Citation: Journal of Hematology & Oncology 2019 12:97
  9. Cancer has become the second most serious disease threatening human health, followed by cardiovascular diseases. This study aimed to quantitatively estimate the mortality, morbidity, and analyze the trends of ...

    Authors: Longfei Lin, Lei Yan, Yuling Liu, Fang Yuan, Hui Li and Jian Ni
    Citation: Journal of Hematology & Oncology 2019 12:96
  10. Adipocytes are one of the primary stromal cells in many tissues, and they are considered to play an active role in the tumor microenvironment. Cancer-associated adipocytes (CAAs) are not only found adjacent to...

    Authors: Qi Wu, Bei Li, Zhiyu Li, Juanjuan Li, Si Sun and Shengrong Sun
    Citation: Journal of Hematology & Oncology 2019 12:95
  11. Antibody-drug conjugates (ADC) represent a distinct family of chemoimmunotherapy agents. ADCs are composed of monoclonal antibodies conjugated to cytotoxic payloads via specialized chemical linkers. ADCs there...

    Authors: Bo Yu and Delong Liu
    Citation: Journal of Hematology & Oncology 2019 12:94

    The Correction to this article has been published in Journal of Hematology & Oncology 2020 13:65

  12. Tumor neoantigen is the truly foreign protein and entirely absent from normal human organs/tissues. It could be specifically recognized by neoantigen-specific T cell receptors (TCRs) in the context of major hi...

    Authors: Tao Jiang, Tao Shi, Henghui Zhang, Jie Hu, Yuanlin Song, Jia Wei, Shengxiang Ren and Caicun Zhou
    Citation: Journal of Hematology & Oncology 2019 12:93
  13. Since the discovery of immune checkpoint proteins, there has been a special interest in developing antibodies that block programmed cell death 1 receptor (PD-1) and programmed cell death receptor ligand 1 (PD-...

    Authors: Akintunde Akinleye and Zoaib Rasool
    Citation: Journal of Hematology & Oncology 2019 12:92
  14. Long non-coding RNAs (lncRNAs) have been associated with non-small cell lung cancer (NSCLC), but the underlying molecular mechanisms of their specific roles in mediating aerobic glycolysis have been poorly exp...

    Authors: Qian Hua, Mingming Jin, Baoming Mi, Fei Xu, Tian Li, Li Zhao, Jianjun Liu and Gang Huang
    Citation: Journal of Hematology & Oncology 2019 12:91

    The Correction to this article has been published in Journal of Hematology & Oncology 2023 16:12

  15. Altered energy metabolism is a hallmark of tumors aiming at supplying necessary nutrients for tumorigenesis and development. These redirected metabolic pathways associated with carbohydrate, lipid and amino ac...

    Authors: Tao Yu, Yanfen Wang, Yu Fan, Na Fang, Tongshan Wang, Tongpeng Xu and Yongqian Shu
    Citation: Journal of Hematology & Oncology 2019 12:90
  16. The treatment of genitourinary malignancies has dramatically evolved over recent years. Renal cell carcinoma, urothelial carcinoma of the bladder, and prostate adenocarcinoma are the most commonly encountered ...

    Authors: Kevin Zarrabi, Azzam Paroya and Shenhong Wu
    Citation: Journal of Hematology & Oncology 2019 12:89
  17. Low-dose post-transplant cyclophosphamide (PTCy) in conjunction with anti-thymocyte globulin (ATG) appears as a potentially effective graft-versus-host disease (GVHD) prevention strategy in haploidentical hema...

    Authors: Yu Wang, De-Pei Wu, Qi-Fa Liu, Lan-Ping Xu, Kai-Yan Liu, Xiao-Hui Zhang, Wen-Jing Yu, Yang Xu, Fen Huang and Xiao-Jun Huang
    Citation: Journal of Hematology & Oncology 2019 12:88
  18. Haploidentical transplantation has been proposed as an effective treatment for severe aplastic anemia (SAA). The majority of patients have more than one HLA-haploidentical donor. Herein, we compared the outcom...

    Authors: Lan-Ping Xu, Shun-Qing Wang, Yan-Ru Ma, Su-Jun Gao, Yi-Fei Cheng, Yuan-Yuan Zhang, Wen-Jian Mo, Xiao-Dong Mo, Yu-Ping Zhang, Chen-Hua Yan, Yu-Hong Chen, Ming Zhou, Yu Wang, Xiao-Hui Zhang, Kai-Yan Liu and Xiao-Jun Huang
    Citation: Journal of Hematology & Oncology 2019 12:87
  19. Among all the stromal cells that present in the tumor microenvironment, cancer-associated fibroblasts (CAFs) are one of the most abundant and critical components of the tumor mesenchyme, which not only provide...

    Authors: Tongyan Liu, Chencheng Han, Siwei Wang, Panqi Fang, Zhifei Ma, Lin Xu and Rong Yin
    Citation: Journal of Hematology & Oncology 2019 12:86
  20. We tested whether a single nucleotide polymorphism (SNP) that affects splicing of CD33 predicted response to treatment in adults with acute myeloid leukemia (AML) who received the novel CD33 antibody-drug conj...

    Authors: Michele Stanchina, Alessandro Pastore, Sean Devlin, Christopher Famulare, Eytan Stein and Justin Taylor
    Citation: Journal of Hematology & Oncology 2019 12:85
  21. Plenty of immune cells infiltrate into the tumor microenvironment (TME) during tumor progression, in which myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of immature myeloid cell...

    Authors: Xinyu Tian, Han Shen, Zhiyang Li, Tingting Wang and Shengjun Wang
    Citation: Journal of Hematology & Oncology 2019 12:84
  22. The original article [1] contains an error in Fig. 2 whereby Fig. 2D has mistakenly been omitted. Fig. 2 can be viewed in its entirety – including Fig. 2D – in this Correction article.

    Authors: Wenwu Xiao, Weijie Ma, Sixi Wei, Qianping Li, Ruiwu Liu, Randy P. Carney, Kevin Yang, Joyce Lee, Alan Nyugen, Ken Y. Yoneda, Kit S. Lam and Tianhong Li
    Citation: Journal of Hematology & Oncology 2019 12:83

    The original article was published in Journal of Hematology & Oncology 2019 12:56

  23. Lymphomas are a heterogeneous group of lymphoproliferative disorders, with unique clinical and biological characteristics that exhibit variable response to therapy. Advances in chemo-immunotherapy have improve...

    Authors: Sabarish Ayyappan and Kami Maddocks
    Citation: Journal of Hematology & Oncology 2019 12:82

    The Correction to this article has been published in Journal of Hematology & Oncology 2021 14:28

  24. Tamoxifen resistance remains a clinical challenge for hormone receptor-positive breast cancer. Recently, dysregulations in autophagy have been suggested as a potential mechanism for tamoxifen resistance. Altho...

    Authors: Ji Wang, Shuduo Xie, Jingjing Yang, Hanchu Xiong, Yunlu Jia, Yulu Zhou, Yongxia Chen, Xiaogang Ying, Cong Chen, Chenyang Ye, Linbo Wang and Jichun Zhou
    Citation: Journal of Hematology & Oncology 2019 12:81
  25. Nucleophosmin-anaplastic lymphoma kinase-expressing (NPM-ALK+) T cell lymphoma is an aggressive neoplasm. NPM-ALK, an oncogenic tyrosine kinase, plays a critical role in this lymphoma. Recently, selective ALK inh...

    Authors: Bhawana George, Suraj Konnath George, Wenyu Shi, Abedul Haque, Ping Shi, Ghazaleh Eskandari, Magnus Axelson, Olle Larsson, Ahmed O. Kaseb and Hesham M. Amin
    Citation: Journal of Hematology & Oncology 2019 12:80

    The Correction to this article has been published in Journal of Hematology & Oncology 2023 16:61

  26. The biological function of protein arginine methyltransferase 3 (PRMT3) is not well known because very few physiological substrates of this methyltransferase have been identified to date.

    Authors: Ming-Chuan Hsu, Ya-Li Tsai, Chia-Hsien Lin, Mei-Ren Pan, Yan-Shen Shan, Tsung-Yen Cheng, Skye Hung-Chun Cheng, Li-Tzong Chen and Wen-Chun Hung
    Citation: Journal of Hematology & Oncology 2019 12:79
  27. While promising, immunotherapy has yet to be fully unlocked for the preponderance of cancers where conventional chemoradiation reigns. This remains particularly evident in pediatric sarcomas where standard of ...

    Authors: Kyle A. Dyson, Brian D. Stover, Adam Grippin, Hector R. Mendez-Gomez, Joanne Lagmay, Duane A. Mitchell and Elias J. Sayour
    Citation: Journal of Hematology & Oncology 2019 12:78
  28. To depict the genomic landscape of Chinese early-stage lung squamous cell carcinoma (LUSC) and investigate its correlation with tumor mutation burden (TMB), PD-L1 expression, and immune infiltrates.

    Authors: Tao Jiang, Jinpeng Shi, Zhengwei Dong, Likun Hou, Chao Zhao, Xuefei Li, Beibei Mao, Wei Zhu, Xianchao Guo, Henghui Zhang, Ji He, Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Chunyan Wu and Caicun Zhou
    Citation: Journal of Hematology & Oncology 2019 12:75
  29. During the 1970s, a Na+-independent, ouabain-insensitive, N-ethylmaleimide-stimulated K+-Cl cotransport mechanism was identified in red blood cells for the first time and in a variety of cell types afterward. Du...

    Authors: A. P. Garneau, S. Slimani, L. E. Tremblay, M. J. Fiola, A. A. Marcoux and P. Isenring
    Citation: Journal of Hematology & Oncology 2019 12:74
  30. Double/triple-hit lymphomas (DHL/THL) account for 5–10% of diffuse large B cell lymphoma (DLBCL) with rearrangement of MYC and BCL2 and/or BCL6 resulting in MYC overexpression. Despite the poor prognosis of DHL, ...

    Authors: Weiping Li, Shiv K. Gupta, Weiguo Han, Ryan A. Kundson, Sara Nelson, Darlene Knutson, Patricia T. Greipp, Sherine F. Elsawa, Eduardo M. Sotomayor and Mamta Gupta
    Citation: Journal of Hematology & Oncology 2019 12:73
  31. Acute myeloid leukemia (AML) patients with a high allelic burden of an internal tandem duplication (ITD)-mutated FMS-like Tyrosine Kinase-3 (FLT3) have a dismal outcome. FLT3ITD triggers the proliferation of the ...

    Authors: Maria Solovey, Ying Wang, Christian Michel, Klaus H. Metzeler, Tobias Herold, Joachim R. Göthert, Volker Ellenrieder, Elisabeth Hessmann, Stefan Gattenlöhner, Andreas Neubauer, Dinko Pavlinic, Vladimir Benes, Oliver Rupp and Andreas Burchert
    Citation: Journal of Hematology & Oncology 2019 12:72
  32. Mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival, metabolism, and immunity. mTOR is usually assembled into several complexes such as mTOR complex 1/2 (mTORC1/2). In c...

    Authors: Hui Hua, Qingbin Kong, Hongying Zhang, Jiao Wang, Ting Luo and Yangfu Jiang
    Citation: Journal of Hematology & Oncology 2019 12:71
  33. Glyphosate is the most widely used herbicide in the USA and worldwide. There has been considerable debate about its carcinogenicity. Epidemiological studies suggest that multiple myeloma (MM) and non-Hodgkin l...

    Authors: Lei Wang, Qipan Deng, Hui Hu, Ming Liu, Zhaojian Gong, Shanshan Zhang, Zijun Y. Xu-Monette, Zhongxin Lu, Ken H. Young, Xiaodong Ma and Yong Li
    Citation: Journal of Hematology & Oncology 2019 12:70
  34. As information on incidence, risk factors, and outcome of acute leukemia (AL) relapse after unmanipulated haploidentical stem cell transplantation (haplo-SCT) is scarce, a retrospective registry study was perf...

    Authors: Simona Piemontese, Ariane Boumendil, Myriam Labopin, Christoph Schmid, Fabio Ciceri, William Arcese, Yener Koc, Zafar Gulbas, Johanna Tischer, Benedetto Bruno, Depei Wu, Didier Blaise, Dietrich Beelen, Giuseppe Irrera, Annalisa Ruggeri, Mohamed Houhou…
    Citation: Journal of Hematology & Oncology 2019 12:68
  35. Small cell lung cancer (SCLC) is one of the deadliest cancer types in the world. Despite the high response rate to frontline platinum-containing doublets, relapse is inevitable for the majority of patients and...

    Authors: Yaru Tian, Xiaoyang Zhai, Anqin Han, Hui Zhu and Jinming Yu
    Citation: Journal of Hematology & Oncology 2019 12:67
  36. The chromosomal rearrangements of the mixed-lineage leukemia gene MLL (KMT2A) have been extensively characterized as a potent oncogenic driver in leukemia. For its oncogenic function, most MLL-fusion proteins ...

    Authors: Krzysztof Brzezinka, Ekaterina Nevedomskaya, Ralf Lesche, Michael Steckel, Ashley L. Eheim, Andrea Haegebarth and Carlo Stresemann
    Citation: Journal of Hematology & Oncology 2019 12:66
  37. Personalized and risk-adapted treatment strategies in multiple myeloma prerequisite feasibility of prospective assessment, reporting of targets, and prediction of survival probability in clinical routine. Our ...

    Authors: Dirk Hose, Susanne Beck, Hans Salwender, Martina Emde, Uta Bertsch, Christina Kunz, Christoph Scheid, Mathias Hänel, Katja Weisel, Thomas Hielscher, Marc S. Raab, Hartmut Goldschmidt, Anna Jauch, Jérôme Moreaux and Anja Seckinger
    Citation: Journal of Hematology & Oncology 2019 12:65
  38. Inflammation has long been accepted as a key component of carcinogenesis. During inflammation, inflammasomes are potent contributors to the activation of inflammatory cytokines that lead to an inflammatory cas...

    Authors: Shengchao Xu, Xizhe Li, Yuanqi Liu, Yu Xia, Ruimin Chang and Chunfang Zhang
    Citation: Journal of Hematology & Oncology 2019 12:64
  39. Chimeric antigen receptor-modified T (CAR-T) cells have achieved significant success in the treatment of several hematological malignancies. However, the translation of the existing achievements into the treat...

    Authors: Jianshu Wei, Xiao Han, Jian Bo and Weidong Han
    Citation: Journal of Hematology & Oncology 2019 12:62
  40. Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. Despite high rates of response to first-line chemotherapy and radiotherapy, patients with extensive-stage disease eventually re...

    Authors: Dwight H. Owen, Michael J. Giffin, Julie M. Bailis, Marie-Anne Damiette Smit, David P. Carbone and Kai He
    Citation: Journal of Hematology & Oncology 2019 12:61
  41. Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with poor prognosis, and its treatment remains a challenge due to few targeted medicines and high risk of relapse, metastasi...

    Authors: Qing Xie, Zhijie Yang, Xuanmei Huang, Zikang Zhang, Jiangbin Li, Jianhua Ju, Hua Zhang and Junying Ma
    Citation: Journal of Hematology & Oncology 2019 12:60
  42. Harnessing the power of the immune system to recognize and eliminate cancer cells is a longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune checkpoint blockade (ICB) and chimeric an...

    Authors: Hao Wang, Gurbakhash Kaur, Alexander I. Sankin, Fuxiang Chen, Fangxia Guan and Xingxing Zang
    Citation: Journal of Hematology & Oncology 2019 12:59
  43. Among all malignant tumors that threaten human health, virus-related tumors account for a large proportion. The treatment of these tumors is still an urgent problem to be resolved. The immune system is the “gu...

    Authors: Peipei Gao, Cordelle Lazare, Canhui Cao, Yifan Meng, Ping Wu, Wenhua Zhi, Shitong Lin, Juncheng Wei, Xiaoyuan Huang, Ling Xi, Gang Chen, Junbo Hu, Ding Ma and Peng Wu
    Citation: Journal of Hematology & Oncology 2019 12:58
  44. Chimeric antigen receptor T (CAR-T) cell therapy simultaneously against CD19 and CD22 is an attractive strategy to address the antigen escape relapse after CD19-directed CAR-T cell therapies. However, the pote...

    Authors: Hejin Jia, Zhenguang Wang, Yao Wang, Yang Liu, Hanren Dai, Chuan Tong, Yelei Guo, Bo Guo, Dongdong Ti, Xiao Han, Qingming Yang, Zhiqiang Wu and Weidong Han
    Citation: Journal of Hematology & Oncology 2019 12:57
  45. α3β1 integrin is a promising cancer biomarker and drug target. We previously identified a 9-amino-acid cyclic peptide LXY30 for detecting α3β1 integrin on the surface of live tumor cells. This study was undert...

    Authors: Wenwu Xiao, Weijie Ma, Sixi Wei, Qianping Li, Ruiwu Liu, Randy P. Carney, Kevin Yang, Joyce Lee, Alan Nyugen, Ken Y. Yoneda, Kit S. Lam and Tianhong Li
    Citation: Journal of Hematology & Oncology 2019 12:56

    The Correction to this article has been published in Journal of Hematology & Oncology 2019 12:83

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here